SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
UPB

Upstream Bio, Inc. (NASDAQ:UPB)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$2.78-$0.08 (-2.80%)
 
Market cap
$152M
Insider Score
Health Score
Analyst consensus
Listed since
Oct 11, 2024
Market Cap$152.38M-89.2%
Revenue (ttm)$2.87M+2.5%
Net Income-$163.94M-34.1%
EPS-$3.02-31.9%
Shares Out54.81M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume891,334
Open$2.94
Previous Close$2.86
Day's Range$2.73 - $2.98
52-Week Range$2.68 - $33.68
Beta1.39
AnalystsBuy
Price Target$25.00(+799.28%)
Earnings DateMar 17, 2027

About UPB

Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.

Address
890 Winter Street, Waltham, MA, 02451, US
Market Cap
152 million
Employees
75
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$58.23K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $51.00 (+1734.5%)

1 firm rating UPB in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From UPB’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-2.80%
5 Days
-13.93%
1 Month
-17.51%
6 Months
-69.42%
1 Year
-89.18%

$UPB stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in UPB holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by UPB's directors and management

Net Shares Purchased by Insiders−6k−3k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

UPB Estimated quarterly lobbying spending

Source: U.S. Senate LDA

UPB Revenue by Segment

$16.93MTotal
Verekitug program$8.98M53.07%
Manufacturing costs$2.83M16.69%
Professional fees and other$2.01M11.87%
Professional fees$1.64M9.70%
Other$1.07M6.34%
Collaboration revenue$395.00K2.33%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New UPB patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to UPB from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in UPB

VTIVanguard Morningstar Total Stock Market ETF$7.60M
IWMiShares Russell 2000 ETF$2.64M
VXFVanguard Extended Market ETF$2.47M
VTWOVanguard Russell 2000 ETF$1.17M
IWNiShares Russell 2000 Value ETF$1.04M
IBBiShares Biotechnology ETF$791.55K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from UPB’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
85
News & Sentiment
38% of score
35

News check: Q3 loss with revenue miss dominates coverage; one positive note on progress insufficient to offset disappointing financial results.

Recent Insider Activity

Buys
0
Sells
10
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BBCVirtus Biotech Clinical Trials ETF0.39%
SBIOALPS Medical Breakthroughs ETF0.10%
FFSMFidelity Fundamental Small-Mid Cap ETF0.04%
FSMOFidelity Fundamental Small-Mid Cap ETF0.04%
IBBQInvesco Nasdaq Biotechnology ETF0.01%
IBBiShares Biotechnology ETF0.01%
BIBProShares Ultra Nasdaq Biotechnology0.01%
VHTVanguard Health Care ETF0.00%

Weight is the stock’s share of each fund’s holdings.